180 related articles for article (PubMed ID: 31905966)
41. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
42. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 expression in triple-negative breast cancer.
Mittendorf EA; Philips AV; Meric-Bernstam F; Qiao N; Wu Y; Harrington S; Su X; Wang Y; Gonzalez-Angulo AM; Akcakanat A; Chawla A; Curran M; Hwu P; Sharma P; Litton JK; Molldrem JJ; Alatrash G
Cancer Immunol Res; 2014 Apr; 2(4):361-70. PubMed ID: 24764583
[TBL] [Abstract][Full Text] [Related]
44. Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS; Schmidt M
Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
[TBL] [Abstract][Full Text] [Related]
45. The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.
Sudarsa IW; Gunawan IPA; Manuaba IBTW
Case Rep Oncol; 2021; 14(1):347-351. PubMed ID: 33776728
[TBL] [Abstract][Full Text] [Related]
46. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
47. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer.
Park IH; Yang HN; Lee KJ; Kim TS; Lee ES; Jung SY; Kwon Y; Kong SY
Oncotarget; 2017 May; 8(20):32722-32730. PubMed ID: 28415798
[TBL] [Abstract][Full Text] [Related]
48. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
50. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
51. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
52. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
53. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
54. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
55. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
56. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
57. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
58. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
Peng F; Xiong L; Peng C
Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
[TBL] [Abstract][Full Text] [Related]
59. Secreted Factors from Adipose Tissue Reprogram Tumor Lipid Metabolism and Induce Motility by Modulating PPARα/ANGPTL4 and FAK.
Blücher C; Iberl S; Schwagarus N; Müller S; Liebisch G; Höring M; Hidrobo MS; Ecker J; Spindler N; Dietrich A; Burkhardt R; Stadler SC
Mol Cancer Res; 2020 Dec; 18(12):1849-1862. PubMed ID: 32859692
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Kolev VN; Tam WF; Wright QG; McDermott SP; Vidal CM; Shapiro IM; Xu Q; Wicha MS; Pachter JA; Weaver DT
Oncotarget; 2017 Aug; 8(31):51733-51747. PubMed ID: 28881682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
